227nok
1,1 %
Date:2025-02-21Time:18:00:00Latest report:Q4-2024List:Oslo BorsTicker:ULTI
Market Cap:458 mnokEnterprise Value:354 mnokNet Sales:- mnokEarnings:-212,7 mnokEmployees:0ISIN:NO0010851603

Ratios

10-year key figure history for Ultimovacs turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Ultimovacs with index and moving average MA50 and MA200.

Stockprice:2,27
MA50:2,26
MA200:3,92
Price/MA200:-42,3 %
RSI (14):58,0
Price/MA50:0,1 %

Description

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Pharmaceuticals